儿童难治性支原体肺炎的抗支原体药物治疗进展

doi:10.5246/jcps.2022.05.029

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (5): 334-342.DOI: 10.5246/jcps.2022.05.029

儿童难治性支原体肺炎的抗支原体药物治疗进展

武海艳¹, 张翔¹, 丁珊珊¹, 张国华¹, 唐琳琳³, 唐琳²^,^*()

1. 山东第一医科大学附属中心医院药学部, 山东济南 250013
2. 山东第一医科大学附属省立医院药学部, 山东济南 250021
3. 潍坊医学院附属医院药学部, 山东潍坊 261041

收稿日期:2021-09-24 修回日期:2021-10-29 接受日期:2021-12-29 出版日期:2022-06-02 发布日期:2022-06-02
通讯作者: 唐琳
作者简介:
+ Tel.: +86-15863188179, E-mail: lintang1989@126.com
基金资助:
Science and Technology Plan Project of Jinan Health Committee (Grant No. 2021-1-08).

Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia

Haiyan Wu¹, Xiang Zhang¹, Shanshan Ding¹, Guohua Zhang¹, Linlin Tang³, Lin Tang²^,^*()

1 Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China
2 Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
3 Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang 261041, Shandong, China

Received:2021-09-24 Revised:2021-10-29 Accepted:2021-12-29 Online:2022-06-02 Published:2022-06-02
Contact: Lin Tang

摘要/Abstract

摘要：

儿童难治性支原体肺炎的发病率呈逐年上升趋势, 且病情进展迅速, 常出现严重的并发症, 遗留后遗症, 严重影响患儿的生活质量。儿童难治性支原体肺炎抗MP药物的品种选择、剂量、疗程给儿科医院带来许多困扰。本文就儿童难治性支原体肺炎治疗的抗MP药物的特点、用法、用量、耐药机制及治疗进展进行了综述, 旨在为儿童难治性支原体肺炎的抗MP药物治疗提供思路。

关键词: 儿童, 难治性支原体肺炎, 抗支原体药物, 治疗, 进展

Abstract:

The incidence of refractory mycoplasma pneumoniae pneumonia (RMPP) in children is increasing year by year, and the disease is progressing rapidly. It is accompanied by serious complications and legacy effects, seriously affecting the quality of life of children. The selection, dosage, and course of anti-MP drugs in children with RMPP have brought a lot of troubles to pediatric hospitals. In the present study, the characteristics, usage and dosage, drug resistance mechanism, and treatment progress of anti-MP drugs for the treatment of RMPP in children were reviewed. Collectively, our findings provided ideas for the treatment of children with RMPP using anti-MP drugs.

Key words: Children, Refractory mycoplasma pneumonia, Anti-mycoplasma drugs, Treatment, Progression

Supporting:

武海艳, 张翔, 丁珊珊, 张国华, 唐琳琳, 唐琳. 儿童难治性支原体肺炎的抗支原体药物治疗进展[J]. 中国药学(英文版), 2022, 31(5): 334-342.

Haiyan Wu, Xiang Zhang, Shanshan Ding, Guohua Zhang, Linlin Tang, Lin Tang. Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 334-342.

图/表 2

参考文献 48

[1]	Ni, X. Dignosis and treatment guideline of community acquired pneumonia in children. Clin. Educ. Gen. Pract. 2019, 09, 771–777.
[2]	Chen, Z.M.; Shang, Y.X.; Zhao, S.Y.; Xin, D.L.; Xu, B.P.; Zeng, Y.J.; Lu, M. Zhang, H.L.; Bao, J. Expert consensus on diagnosis and treatment of mycoplasma pneumoniae pneumonia in children. J. Appl. Clin. Pediatr. 2015, 17, 1304–1308.
[3]	Cao, B.; Qu, J.X.; Yin, Y.D.; Eldere, J.V. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin. Respir. J. 2017, 11, 419–429.
[4]	Yamazaki, T.; Kenri, T. Epidemiology of mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front. Microbiol. 2016, 7, 693.
[5]	Gong, C.H.; Liu, F. Mycoplasma pneumoniae pneumonia in children: a clinical analysis of 293 cases. J. Tongji Univ (Med. Sci.). 2020, 41, 331–337.
[6]	Han, X.H. Treatment of refractory mycoplasma pneumoniae pneumonia in children. Med. Philos. B. 2018, 39, 12–15.
[7]	Liu, X.M.; Jing, S.J. Research progress on risk factors related to refractory Mycoplasma pneumoniae pneumonia. China Mod. Med. 2020, 03, 12–16.
[8]	Zhang, W.C.; Zhao, M.C.; Feng, Z.S.; Li, M.; Guo, Y.H.; Li, G.X. The clinical value of pellet agglutination assay for MP antibody titer and colloidal gold method for simultaneously detection of MP-IgM and MP-IgG in children with mycoplasma pneumonia. J. Hebei Med. Univ. 2018, 39, 1058–1061, 1066.
[9]	Wang, H.; Zhao, S.Y. Research progress in pathogenesis, diagnosis and treatment of mycoplasma pneumoniae pneumonia in children. World Clin. Drugs. 2020, 5, 390–398.
[10]	Li, S.L.; Sun, H.M. Progress in global drug resistance patterns and drug resistance mechanisms of mycoplasma pneumoniae. Chin. J. Microbiol. Immunol. 2018, 5, 5395–5400.
[11]	Cao, B.; Zhao, C.J.; Yin, Y.D.; Zhao, F.; Song, S.F.; Bai, L.; Zhang, J.Z.; Liu, Y.M.; Zhang, Y.Y.; Wang, H.; Wang, C. High prevalence of macrolide resistance in mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 2010, 51, 189–194.
[12]	Waites, K.B. What’s new in diagnostic testing and treatment approaches for Mycoplasma pneumoniae infections in children? Adv. Exp. Med. Biol. 2011, 719, 47–57.
[13]	Atkinson, T.P.; Waites, K.B. Mycoplasma pneumoniae infections in childhood. Pediatr. Infect. Dis. J. 2014, 33, 92–94.
[14]	Zhou, P.X.; Zhou, W.; Wang, X.L.; Zhang, X.L.; Xu, B.P.; Tong, X.M.; Shen, K.L.; Zhai, S.D. Expert consensus on rapid advice guideline for intravenous azithromycin in children. Clin. Med. J. 2019, 17, 39–45.
[15]	Tang, J.Y.; Wang, Q.; Wu, S.J.; Xu, H.P.; Zhang, S.H.; Zhang, G. Efficacy and safety of different-course intravenous azithromycin treatments for mycoplasma pneumonia in children Meta-analysis. China Pharmacist. 2020, 1, 97–100.
[16]	Zheng, Y.; Liu, S.P.; Xu, B.P.; Shi, Z.R.; Wang, K.; Yang, J.B.; Huang, X.; Tang, B.H.; Chen, X.K.; Shi, H.Y.; Zhou, Y.; Wu, Y.E.; Qi, H.; Jacqz-Aigrain, E.; Shen, A.D.; Zhao, W. Population pharmacokinetics and dosing optimization of azithromycin in children with community-acquired pneumonia. Antimicrob. Agents Chemother. 2018, 62, 9.
[17]	Lin, J.T.; Zhang, Y.M.; Wang, C.Z.; Zhou, X.; Huang, M.; Liu, C.T.; Wu, C.G.; Wan, H.Y.; Yu, W.C.; Dai, Y.R. Antibacterial external action of macrolides and expert consensus on clinical application. Chin. J. Internal. Med. 2017, 7, 546–557.
[18]	DiNicolantonio, J.J. Azithromycin for prevention of exacerbations of COPD. N Engl J. Med. 2011, 365, 2235.
[19]	He, W.C.; Zhang, X.J.; Wang, S. Clinical analysis of the combination of modified Huanglian Jiedu Decoction and erythromycin in the treatment of refractory mycoplasma pneumonia. Jilin Med. J. 2020, 12, 2955–2957.
[20]	He, W.C.; Zhang, X.J.; Zhang, W.J. Observation on the therapeutic effect of Qingrejiedu Decoction combined with erythromycin on refractory mycoplasma pneumonia in children. Mod. J. Integr. Tradit. Chin. West. Med. 2020, 20, 2198–2202.
[21]	Liang, Y.T.; Li, L.; Xu, G.M. Clinical effect analysis of low dose methylprednisolone sodium succinate combined with erythromycin in the treatment of children with refractory mycoplasma pneumonia. J. North Pharm. 2020, 07, 92–93.
[22]	Dai, X.Q. Evaluation of Glucocorticoid-assisted Injection of Erythromycin Lactate in the Treatment of Refractory Mycoplasma Pneumoniae Pneumonia in Children. World Latest Med. Inf. 2019, A3, 42–43.
[23]	Han, X.; Miao, N.Y.; Wen, H.M.; Wang, C.H. Minocycline in children with macrolide-resistant mycoplasma pneumoniae pneumonia. J. Pediatr. Pharm. 2016, 22, 17–19.
[24]	Wang, Y.X.; Chu, D.M.; Yao, L.; Wang, B.L. Therapeutic effect of minocycline combined with methylprednisolone sodium succinate in the treatment of refractory mycoplasma pneumoniae pneumonia. Shandong Med. J. 2013, 44, 52–53.
[25]	Chen, Z.M.; Zhao, Y.S.; Wang, Y.S.; Lu, Q.; Zheng, Y.J.; Liu, Y.; Lu, J.R.; Yang, D.H. Some problems of mycoplasma pneumoniae infection. Chin. J. Pediatr. 2016, 02, 84–87.
[26]	Korean Centers for Disease Control and Prevention, Korean National Institute of Health. Korean Antimicrobial Resistance Monitoring System annual report. Chungbuk: The Centers. 2011.
[27]	Chen, Y.; Xue, F.; Zhang, Y.F. Clinical observation of minocycline adjuvant therapy for refractory mycoplasma pneumoniae pneumonia. J. Clin. Pediatr. 2012, 8, 795.
[28]	Infectious Diseases Committee of China Medical Education Association. Expert consensus on clinical application of antimicrobial pharmacokinetic/pharmacodynamics theory. Chin. J. Union Respiration. 2018, 6, 409–446.
[29]	Product Information: MINOCIN(R) oral suspension, minocycline hcl oral suspension. Triax Pharmaceuticals, LLC, Cranford, NJ. 2010.
[30]	Product Information: minocycline HCl oral tablets, minocycline HCl oral tablets. Par Pharmaceutical Companies, Inc. (per Manufacturer), Spring Valley, NY. 2011.
[31]	Product Information: MINOCIN(R) pellet-filled oral capsules, minocycline hcl pellet-filled oral capsules. Triax Pharmaceuticals, LLC, Cranfrod, NJ. 2010.
[32]	Yang, X.; Qin, X.G.; Xin, D.L. The clinical analysis of the minocycline hydrochloride treatment for children with mycoplasmal pneumonia. Chin. Med. Rec. 2013, 14, 64–66.
[33]	Duan, L.F.; Zhou, J. Medication consultation on minocycline administration in a 4-year-old with refractory Mycoplasma pneumoniae and literature review. Cent. South Pharm. 2020, 11, 1928–1931.
[34]	Zeng, N.; Wang, X.J.; Sun, H.J. Safety analysis of minocycline in the treatment of refractory mycoplasma pneumoniae pneumonia in children. Pharm. Care Res. 2020, 20, 137–139.
[35]	Okada, T.; Morozumi, M.; Tajima, T.; Hasegawa, M.; Sakata, H.; Ohnari, S.; Chiba, N.; Iwata, S.; Ubukata, K. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin. Infect. Dis. 2012, 55, 1642–1649.
[36]	Yang, H.J. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J. Pediatr. 2019, 62, 199–205.
[37]	Zeng, N.; Wang, X.J.; Sun, H.J. Safety analysis of minocycline in the treatment of refractory Mycoplasma pneumoniae pneumonia in children. Pharm. Care Res. 2020, 20, 137–139.
[38]	Wu, J.Y.; Sun, S.M. Expert consensus on the use of fluoroquinolones in children. Pharm. Today. 2018, 01, 1–10.
[39]	Guiding Principles of Clinical Application of Antibacterial Agents (2015 Edition), Beijing: People’s Health Publishing House. 2015, 57.
[40]	Jiang, Z.F.; Shen, K.L.; Shen, Y.; Zhu, F.T. Practical Pediatrics. 8th Edition. Beijing: People’s Medical Publishing House. 2015.
[41]	Averbuch, D.; Hidalgo-Grass, C.; Moses, A.E.; Engelhard, D.; Nir-Paz, R. Macrolide resistance in mycoplasma pneumoniae, Israel, 2010. Emerg. Infect. Dis. 2011, 17, 1079–1082.
[42]	Cardinale, F.; Chironna, M.; Dumke, R.; Binetti, A.; Daleno, C.; Sallustio, A.; Valzano, A.; Esposito, S. Macrolide-resistant mycoplasma pneumoniae in paediatric pneumonia. Eur. Respir. J. 2011, 37, 1522–1524.
[43]	Lin, M.; Shi, L.; Huang, A.; Liang, D.; Ge, L.; Jin, Y. Efficacy of levofloxacin on macrolide-unresponsive and corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children. Ann. Palliat. Med. 2019, 8, 632–639.
[44]	Dai, F.F.; Liu, F.Q.; Chen, X.; Yang, J.; Wang, K.; Guo, C.Y. The treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. J. Clin. Pharm. Ther. 2021, 46, 705–710.
[45]	Liang, S.J. Clinical effect analysis of quinolones in the treatment of children with refractory mycoplasma pneumoniae pneumonia and its effect on immune function. Shenyang: China Med. Univ. 2020.
[46]	Liu, L.M.; Yuan, Y.H.; Xie, M.Y.; Gu, R.; Zhao, X.D. Musculoskeletal adverse drug events of levaquin in children: a systematic review. Chin. J. Evid. Based Pediatr. 2015, 10, 193–197.
[47]	Bradley, J.S.; Kauffman, R.E.; Balis, D.A.; Duffy, C.M.; Gerbino, P.G.; Maldonado, S.D.; Noel, G.J. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014, 134, e146–e153.
[48]	Patel, K.; Goldman, J.L. Safety concerns surrounding quinolone use in children. J. Clin. Pharmacol. 2016, 56, 1060–1075.

儿童难治性支原体肺炎的抗支原体药物治疗进展

Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕雯, 付颖. Graves眼病的免疫靶向治疗的研究进展[J]. 中国药学(英文版), 2023, 32(8): 616-625.
[2]	吴悔, 宁港, 李波男, 周兴. Nrf2对睾丸微环境的影响及其在男性疾病中的研究进展[J]. 中国药学(英文版), 2023, 32(7): 513-526.
[3]	万敏, 刘金玉, 喻光燚, 童绥菊, 柯磊, 张玉, 游如旭. 基于WHO/HAI标准调查方法的武汉市骨质疏松治疗药物的可获得性及可负担性分析[J]. 中国药学(英文版), 2023, 32(5): 417-425.
[4]	苏俐玫, 毛溪悦, 阳丽梅. 肺癌患者静脉血栓栓塞预防的疗效与安全性的meta分析[J]. 中国药学(英文版), 2023, 32(10): 852-860.
[5]	杨东升, 魏宁漪, 牛剑钊, 许鸣镝. 治疗等效性评价代码介绍及其对我国仿制药参比制剂选择的影响[J]. 中国药学(英文版), 2022, 31(8): 646-651.
[6]	严荧燕, 毛佩芝, 陈漪, 沈珑慧. 儿童医院门急诊布洛芬和对乙酰氨基酚交替使用分析[J]. 中国药学(英文版), 2022, 31(5): 369-373.
[7]	杨杰, 孟海阳, 李朵璐, 王艳英, 古兆森, 张晓坚. 国内中西医结合病房的药物治疗相关问题研究[J]. 中国药学(英文版), 2022, 31(4): 279-288.
[8]	冯书云, 陈朋举, 王宁, 赵博, 卢奕帆, 张永恒. 老年慢性病患者合作药物治疗管理模式的探索[J]. 中国药学(英文版), 2022, 31(11): 866-876.
[9]	李苗, 孔晓岩, 王淑梅. 血液系统恶性肿瘤患儿甲氨蝶呤清除延迟危险因素的回顾性分析[J]. 中国药学(英文版), 2022, 31(10): 746-754.
[10]	刘雅婕, 王雨, 李佳佳, 许晓庆, 李馨儒. 载阿霉素-芦米司匹多囊脂质体的制备及体内外评价[J]. 中国药学(英文版), 2021, 30(9): 736-742.
[11]	骆少红, 董凉凉, 李逸元, 徐丹, 陈敏. 酪氨酸激酶抑制剂 (吉非替尼、厄洛替尼、阿法替尼和奥希替尼)一线治疗表皮生长因子受体突变的晚期非小细胞肺癌的成本-效果分析[J]. 中国药学(英文版), 2021, 30(3): 253-263.
[12]	周毅, 赖俊莉, 邱峰, 张军. 高效液相色谱法常规监测中国胃肠间质瘤患者体内的伊马替尼血药浓度[J]. 中国药学(英文版), 2020, 29(9): 637-648.
[13]	吴朝晖, 林慧芬, 林玮玮, 刘亦伟, 游翔, 林翠鸿, 林荣芳, 曾大勇, 黄品芳. 中国成人万古霉素稳态谷浓度与疗效和安全性相关性的前瞻性队列研究[J]. 中国药学(英文版), 2020, 29(5): 341-354.
[14]	薛钧升, 王思媛, 郝方然, 田秀云, 苏红, 杨亮, 安启明, 郝纯毅, 周田彦. 多巴胺增强舒尼替尼治疗胰腺癌的药效[J]. 中国药学(英文版), 2020, 29(10): 689-700.
[15]	李文哲, 袁霞, 徐波, 宋书香. 多色免疫组化/荧光联合多光谱成像技术在肿瘤免疫治疗领域的应用[J]. 中国药学(英文版), 2020, 29(10): 734-747.